Abstract:Introduction: Cardiovascular diseases have been the leading causes of death all over the world for decades. Vascular smooth muscle cells (VSMCs) form a major section of a blood vessel, conferring structural and physiological support to withstand any change under physiological or pathological conditions. VSMC phenotypic modulation from a contractile phenotype to a synthetic state is pivotal for the development of several vascular diseases such as neointima formation after angioplasty and atherosclerosis. Decreased expression of VSMC differentiation markers including SM ɑ-actin (Acta2), SM-myosin heavy chain (Myh11) and SM22 alpha (Tagln) indicates VSMC phenotypic switching, which is accompanied by increasing VSMC proliferation, migration and synthesis of metalloproteinase[1]. However, the molecular mechanisms that underlie VSMC phenotypic switching remain largely unknown. SMYD2, a SET and MYND domain-containing protein, belongs to the SMYD family of protein lysine methyltransferases. Structurally, SET domain regulates lysine methylation of target proteins (as involved in transcription, cell differentiation and cell proliferation), while zinc finger motif MYND domain may interact with proline rich regions and facilitate protein-protein interaction. SMYD2 was originally reported to methylate histone 3 at lysine 4 (H3K4) and lysine 36 (H3K36) and H4 at lysine 20 (H4K20), and plays an essential role in HIV-1 latency and cardiac development [2-3]. Some studies found that SMYD2 can also methylate non-histone proteins such as p53, Hsp90, and Rb and regulate their functions [4-6]. Interestingly, SMYD2 has recently been implicated in human patients with abdominal aortic aneurysm in GWAS screening [7]. The aim of this study is to investigate the role of SMYD2 in the control of VSMC phenotypic switching and neointima formation. Methods: We used Western blotting and PCR to assess SMYD2 expression and VSMC marker gene expression in VSMC phenotypic change in vitro and murine carotid ligation injury model in vivo. In the ligation injury model, right common carotid artery (CCA) was ligated and harvested after 7, 14, and 28 days. SMYD2smc-/- (SMYD2 conditional knockout in VSMCs) mice and SMYD2flox/flox (SMYD2 flox control) mice were subjected to ligation model and CCA was obtained for histological evaluation after7 days, 14 days and 28days. Primary VSMCs were isolated from SMYD2smc-/- mice and SMYD2flox/flox mice and then VSMC marker gene expression was examined by Western blotting and PCR. Furthermore, we also checked expression of SMYD2 in murine atherosclerosis which is closely related to VSMC phenotypic change. Results: The expression of SMYD2 significantly decreased in response to platelet-derived growth factor BB (PDGF-BB) in the serum-starved VSMCs. In the in vivo model, we found that SMYD2 expression was also reduced in the injured versus sham-operated carotid arteries. In comparison with normal healthy arteries, atherosclerotic arteries have a substantially decreased SMYD2 expression in mouse vascular tissues. Moreover, SMYD2 ablation in VSMCs significantly exacerbated ligation injury-induced neointima formation in mice and drastically inhibited VSMC marker gene expression. Conclusion: Our findings demonstrated that SMYD2 down-regulation in VSMCs promotes VSMC phenotypic changing and neointima formation after injury, suggesting that SMYD2 may function as a novel inhibitor of vascular remodeling associated with physical injury and atherosclerotic disease. Disclosure: Nothing to disclose

The lysine methyltransferase SMYD2 facilitates neointimal hyperplasia by regulating the HDAC3–SRF axis

Inhibition of Polycomb Repressor Complex 2 Ameliorates Neointimal Hyperplasia by Suppressing Trimethylation of H3K27 in Vascular Smooth Muscle Cells.

Set and MYND Domain-containing Protein 2 (SMYD2) is a Critical Regulator for Vascular Smooth Muscle Cell Phenotypic Switching and Neointima Formation

Methyltransferase Like 3-Mediated N6-methylatidin Methylation Inhibits Vascular Smooth Muscle Cells Phenotype Switching Via Promoting Phosphatidylinositol 3-Kinase Mrna Decay.

H3K4 Methyltransferase Smyd3 Mediates Vascular Smooth Muscle Cell Proliferation, Migration, and Neointima Formation

SMYD2 regulates vascular smooth muscle cell phenotypic switching and intimal hyperplasia via interaction with myocardin

m6A Modification of Profilin-1 in Vascular Smooth Muscle Cells Drives Phenotype Switching and Neointimal Hyperplasia via Activation of the p-ANXA2/STAT3 Pathway

Epigenetic regulation of vascular smooth muscle cell phenotypic switch and neointimal formation by PRMT5

M 6 A Modification of Profilin-1 in Vascular Smooth Muscle Cells Drives Phenotype Switching and Neointimal Hyperplasia Via Activation of the P-Anxa2/stat3 Pathway

Critical roles of SMYD2 lysine methyltransferase in mediating renal fibroblast activation and kidney fibrosis

Glycolysis and de novo fatty acid synthesis cooperatively regulate pathological vascular smooth muscle cell phenotypic switching and neointimal hyperplasia

SMYD3–PARP16 axis accelerates unfolded protein response and mediates neointima formation

Critical Role of Histone Demethylase Jumonji Domain-Containing Protein 3 in the Regulation of Neointima Formation Following Vascular Injury

SUV39H1 mediated regulation of KLF4 and KDM4A coordinate smooth muscle cell phenotypic plasticity

Sirt1 Acts As A Modulator of Neointima Formation Following Vascular Injury in Mice

Myeloid-derived growth factor suppresses VSMC dedifferentiation and attenuates postinjury neointimal formation in rats by activating S1PR2 and its downstream signaling

CircSMAD3 represses VSMC phenotype switching and neointima formation via promoting hnRNPA1 ubiquitination degradation

Deficiency of smooth muscle cell ILF3 alleviates intimal hyperplasia via HMGB1 mRNA degradation-mediated regulation of the STAT3/DUSP16 axis

P4HA2-induced prolyl hydroxylation of YAP1 restricts vascular smooth muscle cell proliferation and neointima formation

MicroRNA-302a Promotes Neointimal Formation Following Carotid Artery Injury in Mice by Targeting PHLPP2 Thus Increasing Akt Signaling

SMYD2-Methylated PPARγ Facilitates Hypoxia-Induced Pulmonary Hypertension by Activating Mitophagy